The US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) has advised the agency to clarify the scope of the allergy contraindication for Pfizer Inc./BioNTech SE’s COVID-19 vaccine.
At a 12 December emergency meeting convened hours after FDA's Friday night emergency use authorization for the vaccine, ACIP members voted unanimously, with the exception of three members who were...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?